Dr. Scott Kamelle

John Charlson is an Oncologist practicing medicine in Milwaukee, Wisconsin. Dr. Charlson is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, and Undifferentiated Pleomorphic Sarcoma. Dr. Charlson is board certified in Medical Oncology. Dr. Charlson is currently accepting new patients.

Dr. Kurzrock is a world-renowned leader in precision oncology and rare cancers research. She is the Associate Director of Clinical Research for the Medical College of Wisconsin Cancer Center, Associate Director of Precision Oncology at the Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine and the founding director of the Michels Rare Cancers Research Laboratories at the MCW Cancer Center. She is recognized as one of the world’s 25 most important voices in precision medicine and one of the most highly cited scientists globally. She has authored over 950 scientific and medical publications. Dr. Kurzrock is the Chair for the Early Therapeutics and Rare Cancers Committee (SWOG NCI) — one of the largest clinical trials cooperative groups in the country — and has been the principal investigator for more than 100 early-phase clinical trials, leading eight life-changing drugs to FDA approval. In 2022, Dr. Kurzrock and the DART rare cancer study team received the National Cancer Institute Director’s Award of Merit for outstanding work. Dr. Kurzrock is highly rated in 37 conditions, according to our data. Her clinical expertise encompasses PIK3CA-Related Overgrowth Spectrum, Castleman Disease, Multicentric Castleman Disease (MCD), Lymphoid Hyperplasia, and Tissue Biopsy. Dr. Kurzrock is board certified in Internal Medicine and Medical Oncology. Dr. Kurzrock is currently accepting new patients.

Parameswaran Hari is an Oncologist practicing medicine in Milwaukee, Wisconsin. Dr. Hari is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Primary Amyloidosis, Bone Marrow Transplant, and Splenectomy.